# A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

> **NCT07169331** · PHASE4 · RECRUITING · sponsor: **BeiGene** · enrollment: 18 (estimated)

## Conditions studied

- Waldenström's Macroglobulinemia

## Interventions

- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT07169331
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07169331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07169331, "A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07169331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*